Lanier Biotherapeutics announced that the United States Patent and Trademark Office has issued U.S. Patent 11,492,397, entitled, “Neutralizing Monoclonal Antibodies to IL-25 and Uses Thereof.” The patent covers...
Lantheus Holdings (NASDAQ:LNTH) and POINT Biopharma Global (NASDAQ:PNT) announced a set of strategic collaboration agreements in which Lantheus would license exclusive worldwide rights to POINT’s PNT2002 and PNT2003...
Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) signed an exclusive commercial distribution agreement for the Republic of Korea with Medicox, an emerging biotech company with proven partnerships in the Korea. The agreement...
William Blair initiated coverage of Janux Therapeutics (NASDAQ:JANX) with an “outperform” rating based on the potential of the company’s TRACTr platform, which facilitates the generation of conditionally active T-cell...
BTIG downgraded OncoSec Medical (NASDAQ:ONCS) to “neutral” from “buy” and removed its price target after the company reported updated Phase 2 Keynote-695 study results. The stock closed at $4.66 on Nov. 11. Analyst...
Leede Jones Gable downgraded Medical Facilities (TSX:DR) to “hold” from “buy” and lowered its price target to $9.25 (Canadian) from $12, citing solid top-line data in the third quarter of 2022, offset by cost pressures...
CytoSorbents (NASDAQ:CTSO) has received a research grant from a division of the NIH to test the ability of its existing polymers to remove cytokines and lipopolysaccharide (LPS) endotoxin from septic porcine plasma, a...
Hepion Pharmaceuticals’ (NASDAQ:HEPA) chief scientific officer, Daren Ure, Ph.D., will present data highlighting the poly-indication potential of the company’s lead drug candidate, rencofilstat, at the upcoming 6th...
Hepion Pharmaceuticals (NASDAQ:HEPA) is presenting two poster presentations highlighting its lead drug candidate, rencofilstat, at the Liver Meeting 2022, to be hosted by the American Association for the Study of Liver...
Rhythm Pharmaceuticals (NASDAQ:RYTM) plans to initiate a Phase 3 clinical trial in acquired hypothalamic obesity in early 2023, following recent discussions with the FDA. The Phase 3 clinical trial will enroll 120...
Atossa Therapeutics (NASDAQ:ATOS) is acquiring 19.99% of the capital stock of closely-held Dynamic Cell Therapies for $2-million, in addition to $3-million previously paid to Dynamic, “This investment in Dynamic...
Maxim Group raised its price target for Reviva Pharmaceuticals (NASDAQ:RVPH) to $10 from $3 after the company’s ongoing Phase 3 study in schizophrenia reached more than 30% enrollment, of total 400 patients, at sites in...